In the past week, AUPH stock has gone down by -7.09%, with a monthly gain of 10.74% and a quarterly surge of 25.04%. The volatility ratio for the week is 5.02%, and the volatility levels for the last 30 days are 4.49% for Aurinia Pharmaceuticals Inc The simple moving average for the past 20 days is -1.75% for AUPH’s stock, with a 41.83% simple moving average for the past 200 days.
Is It Worth Investing in Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) Right Now?
The 36-month beta value for AUPH is at 1.24. Analysts have varying views on the stock, with 3 analysts rating it as a “buy,” 3 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for AUPH is 128.77M, and currently, shorts hold a 4.83% of that float. The average trading volume for AUPH on December 19, 2024 was 1.27M shares.
AUPH) stock’s latest price update
The stock price of Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) has plunged by -1.07 when compared to previous closing price of 9.10, but the company has seen a -7.09% decline in its stock price over the last five trading sessions. 247wallst.com reported 2024-12-15 that The year is winding down, and the stock markets are near all-time highs. Opinions on what the new year will bring vary wildly.
Analysts’ Opinion of AUPH
Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see AUPH reach a price target of $25, previously predicting the price at $34. The rating they have provided for AUPH stocks is “Overweight” according to the report published on May 05th, 2022.
Oppenheimer gave a rating of “Outperform” to AUPH, setting the target price at $31 in the report published on December 10th of the previous year.
AUPH Trading at 9.88% from the 50-Day Moving Average
After a stumble in the market that brought AUPH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -15.62% of loss for the given period.
Volatility was left at 4.49%, however, over the last 30 days, the volatility rate increased by 5.02%, as shares surge +9.59% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +33.78% upper at present.
During the last 5 trading sessions, AUPH fell by -6.81%, which changed the moving average for the period of 200-days by +63.59% in comparison to the 20-day moving average, which settled at $9.16. In addition, Aurinia Pharmaceuticals Inc saw 0.14% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AUPH starting from TANG KEVIN, who purchase 500,000 shares at the price of $9.09 back on Dec 09 ’24. After this action, TANG KEVIN now owns 8,429,500 shares of Aurinia Pharmaceuticals Inc, valued at $4,545,000 using the latest closing price.
TANG KEVIN, the Director of Aurinia Pharmaceuticals Inc, purchase 400,000 shares at $9.01 during a trade that took place back on Dec 06 ’24, which means that TANG KEVIN is holding 7,929,500 shares at $3,604,000 based on the most recent closing price.
Stock Fundamentals for AUPH
Current profitability levels for the company are sitting at:
- -0.09 for the present operating margin
- 0.87 for the gross margin
The net margin for Aurinia Pharmaceuticals Inc stands at -0.1. The total capital return value is set at -0.04. Equity return is now at value -5.78, with -4.08 for asset returns.
Currently, EBITDA for the company is -63.05 million with net debt to EBITDA at 39.83. When we switch over and look at the enterprise to sales, we see a ratio of 6.07. The receivables turnover for the company is 6.04for trailing twelve months and the total asset turnover is 0.4. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.60.
Conclusion
In conclusion, Aurinia Pharmaceuticals Inc (AUPH) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
